NASDAQ · Medical - Diagnostics & Research

Genetic Technologies Limited (GENE) Stock

$0.77 +0.00% NASDAQ: GENE Healthcare

Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States.

Valuation

MetricValue
Price$0.77
Market Cap$111.24M
P/E Ratio-0.40
P/B Ratio2.75
P/S Ratio20.73
EPS (TTM)$-2.73
52-Week High$3.59
52-Week Low$0.67
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-184.98%
ROA-194.25%
ROCE-613.25%
Gross Margin50.94%
Operating Margin-159.30%
Net Margin-156.78%
Debt/Equity0.48
Current Ratio0.88

Annual Financials (USD)

Metric20202021202220232024
Revenue$1.0M$0$7.0M$10.0M$8.0M
Operating Profit$-6.0M$-7.0M$-8.0M$-10.0M$-12.0M
Net Profit$-6.0M$-7.0M$-7.0M$-12.0M$-12.0M
EPS$-4.50$-2.48$-2.32$-3.60$-2.73
Op Margin-708.8%-6156.2%-111.0%-100.7%-159.3%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$16.0M$23.0M$21.0M$15.0M$6.0M
Total Liabilities$2.0M$1.0M$4.0M$4.0M$4.0M
Cash$14.0M$21.0M$12.0M$8.0M$1.0M
Borrowings$0$0$1.0M$1.0M$1.0M

Latest News

General Dynamics (GD) Q2 2026 Earnings Call Transcript Motley Fool · Aug 8, 2026 Aspen Aerogels Q2 Earnings Call Highlights MarketBeat · Aug 7, 2026 3 Cheap Auto Stocks for Your Short List Zacks · Aug 7, 2026 MP Earnings Show Chinese Rare-Earth Monopoly Is Fading. The Stock Is Up. Barrons.com · Aug 7, 2026 General Dynamics Unit Wins $1.3 Billion Army National Guard IT, Cybersecurity Contract MT Newswires · Aug 7, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-6.0M$-6.0M$-6.0M$-10.0M$-10.0M
Investing Cash Flow$0$-1.0M$-4.0M$0$0
Financing Cash Flow$-3.0M$-2.0M$0$-1.0M$0
Net Cash Flow$12.0M$7.0M$21.0M$-4.0M$-7.0M
Free Cash Flow$-6.0M$-7.0M$-6.0M$-10.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-0.84
FCF Yield-8.99%
Quick Ratio0.83
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AUGXAugmedix, Inc. $2.35 -0.21% -5.33 $115.91M 0.00%
CYTCyteir Therapeutics, Inc. $3.02 -2.27% -2.42 $108.71M 0.00%
GTHGenetron Holdings Limited $4.03 +0.12% -0.95 $127.29M 0.00%
HLVXHilleVax, Inc. $2.09 -0.48% -9.09 $104.76M 0.00%
ICADiCAD, Inc. $3.87 +3.75% -18.43 $106.31M 0.00%

About Genetic Technologies Limited

Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test specifically designed for non-hereditary breast cancer. This innovative test is promoted to various medical specialists, including professionals in breast healthcare and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment experts like breast surgeons. Beyond BREVAGenplus, the company's portfolio includes other cancer risk assessment tests marketed under the 'GeneType' brand, notably 'GeneType for Colorectal Cancer' and 'GeneType for Breast Cancer'. Furthermore, Genetic Technologies is actively developing additional risk assessment tools for a diverse range of conditions, such as cardiovascular diseases, type 2 diabetes, prostate cancer, and melanoma. Its services extend to general genetic testing, encompassing applications in medical, animal, forensic, and plant diagnostics. Genetic Technologies maintains active research and collaboration agreements with several prestigious institutions, including the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, The Ohio State University, and Shivom. The company was established in 1987 and operates from its headquarters in Fitzroy, Australia.

Genetic Technologies Limited is headquartered in AU.

Genetic Technologies Limited (GENE) stock trades at $0.77 with a market capitalization of $111.24M. The stock is valued at a price-to-earnings (P/E) ratio of -0.40, price-to-book of 2.75, price-to-sales of 20.73. Over the past 52 weeks the stock has ranged between $0.67 and $3.59, and currently trades 78.6% below its 52-week high.

On profitability, Genetic Technologies Limited generates a return on equity (ROE) of -184.98%, return on capital employed of -613.25%, an operating margin of -159.30%, a net profit margin of -156.78%.

Official website: www.gtglabs.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides